Recommended

Sarepta’s DMD drug Elevidys issued FDA label update
Rare disease gene therapy granted European first approval
Johnson & Johnson agrees $3bn oncology acquisition
European Commission grants EU first for J&J’s Simponi biosimilar
Researchers validate approach that supports animal-based pyrogen test replacement
ON DEMAND webinar: automating QC testing for radiopharmaceutical production
Insmed secures EU approval for Brinsupri (brensocatib)
Moderna invests over $140m to onshore mRNA medicine manufacturing in US
news

Acquisition deal to back European biosimilars market

1
SHARES

Following the acquisition from Viatris, Biocon Biologics and its partners state that they will commercialise biosimilar products in 31 European countries.

Acquisition deal to back European biosimilars market

Biocon Biologics Ltd has successfully completed integration of Viatris’ biosimilar business in 31 European countries.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Following the acquisition of substantially all global biosimilar business of Viatris in November 2022, and the related integration of over 70 emerging market countries in July 2023 and North America in September 2023, now that Viatris’ biosimilars operations have fully transitioned to Biocon Biologics Ltd in Europe, the company declared that this “represents another significant milestone.”

As a result of the deal, Biocon Biologics and its partners state that they will commercialise these products in the following countries: Albania, Austria, Belgium, Bosnia, Bulgaria, Croatia,  Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, and the UK.

A report by Act4Biosimilars published earlier this month, highlighted that to support the adoption of these medicines and widen patient access across Europe, measures must be put in place to lower the financial burden of developing these medicines.

EPR Podcast Episode 21 – Biosimilars – Salim Benkhalifa, Celltrion Healthcare France

Europe’s biosimilars market

In Europe, Biocon Biologics portfolio includes seven biosimilars: Insulin Aspart and Insulin Glargine, Bevacizumab, Pegfilgrastim, Trastuzumab, Adalimumab, and Etanercept. 

The company stated that based on the IQVIA’s 2022 report: The impact of biosimilar competition in Europe, as of 2022 “the cumulative savings at list prices from the impact of biosimilar competition in Europe reached over €30 billion. Furthermore, since the launch of biosimilars these provided nearly 4.5 billion patient treatment days to European patients.”

As reported by EPR in October this year, Marechal-Jamil, Director Biosimilar Policy & Science at Medicines for Europe shared: “So far, biosimilar medicines have delivered huge access benefits for patients and savings for healthcare budgets… We need to jump start the multistakeholder policy process ensuring more biosimilar medicines development and access, as patient demand for biological medicines increases.”

“As we continue to drive innovation and invest in the future, our mission is singularly focused on the development, manufacturing, distribution, and commercialisation of these medicines in Europe and in the world,” affirmed Jozef Belcik, Head of Commercial Europe & JANZ, Biocon Biologics Ltd. 

Share via
Share via